Explore the Potential with AI-Driven Innovation
This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.
Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.
The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.
Our high-tech, dedicated method is applied to construct targeted libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our strategy employs molecular simulations to explore an extensive range of proteins, capturing their dynamics both individually and within complexes with other proteins. Through ensemble virtual screening, we address proteins' conformational mobility, uncovering key binding sites at both functional regions and remote allosteric locations. This comprehensive investigation ensures a thorough assessment of all potential mechanisms of action, with the goal of discovering innovative therapeutic targets and lead molecules across across diverse biological functions.
Our library stands out due to several important features:
partner
Reaxense
upacc
Q6UVJ0
UPID:
SAS6_HUMAN
Alternative names:
-
Alternative UPACC:
Q6UVJ0; D3DT55; Q8N3K0
Background:
Spindle assembly abnormal protein 6 homolog plays a pivotal role in centriole duplication and biogenesis, ensuring the 9-fold symmetry of centrioles. It is crucial for both mother-centriole-dependent duplication and deuterosome-dependent centriole amplification in multiciliated cells, involving the recruitment of STIL for centriole amplification.
Therapeutic significance:
Linked to Microcephaly 14, primary, autosomal recessive, a condition characterized by significantly reduced head circumference and brain weight, this protein's dysfunction highlights its potential as a target for therapeutic intervention.